Company: RGBP
Filing Date: 2025-04-07
Form Type: 8-K
Source: 0001641172-25-002908
Chunk: 0

Company: Regen BioPharma Inc
Filing Date: 2025-04-07
Form: 8-K
Item: Item 4.01
Chunk 0
---
Item
4.01 Changes in Registrant’s Certifying Accountant.

On
March 31, 2025 the Board of Directors of Regen Biopharma, Inc. (the “ Registrant”), acting as the Registrant’s Audit
Committee, approved the engagement of BCRG Group (“ BCRG”) as its independent auditor. On same date, the accounting firm of
BCRG was engaged as the Registrant’s new independent registered public accounting firm.

On
March 31, 2025 the Board of Directors of the Registrant, acting as the Registrant’s Audit Committee, approved the dismissal of Bush and Associates CPA LLC (“ Bush’)

(a)
Since May 28, 2024 (the date on which Bush has been engaged as the Registrant’s independent registered public accounting firm)
Bush has completed its review of the interim financial statements of the Registrant for the period ended June 30, 2024 and has conducted
no audit of the Registrant’s financial statements.

(c)
During the Company’s two most recent fiscal years and the subsequent interim periods thereto, and in connection with the audit
of the Company’s financial statements for such periods, there were no disagreements between the Company and Bush on any matter
of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved
to the satisfaction of Bush, would have caused Bush to make reference to the subject matter of such disagreements in connection with
its audit reports on the Company’s financial statements.

(d)
The Company provided Bush with a copy of this disclosure set forth under this Item 4.01 and has requested Bush to furnish a letter addressed
to the Securities & Exchange Commission stating whether or not Bush agrees with the above statements. As of April 4, 2025 no response
has been received by the Company from Bush. A copy of this letter from Bush will be filed as Exhibit 16.1 to an amendment to this Current
Report upon receipt of such letter by the Company.

SIGNATURE

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                     REGEN BIOPHARMA, INC.                                   
  Dated:             By:                        /s/                          
                                                David                        
                                                Chairman